Necessary Versus Sufficient: An Increasingly Relevant Distinction in Oncology (ref to ovarian cancer)

clinical oncology article (Markman)

 In summary, it is essential that any organization, as well as individual clinicians attempting to interpret the results of clinical studies, appreciate the critical distinction between what is appropriately considered to be necessary evidence versus the ultimate mandate for sufficient evidence in the future development of specific medical recommendations, evidence-based guidelines, or public health policy.

 References

1. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicenter, open-label, proof-of-concept, randomized, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324-1334, PMID: 26342236.
2. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomized controlled trial. Lancet. [Epub ahead of print]. DOI: http://dx.doi.org/​10.1016/​S0140-6736(15)01224-6.
3. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22): 2295-2303, PMID: 21642681.
4. Grady D. Early detection of ovarian cancer may become possible. The New York Times. December 18, 2015. http://goo.gl/​WN7CPT. Accessed December 22, 2015.